dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: SLC28 family (type: transporter)
Target: Solute carrier family 28 member 3

Ligand: compound 16 [PMID: 19097778] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.539999961853027 pKi
Reference (Journal): Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.
Published in: Bioorg Med Chem Lett
Target family: SLC29 family (type: transporter)
Target: Equilibrative nucleoside transporter 1

Ligand: ticagrelor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2010), FDA (2011)
Primary target: no
Median affinity: 7.300000190734863 pKi
Reference (Journal): Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.
Published in: J Cardiovasc Pharmacol Ther

Ligand: [3H]nitrobenzylmercaptopurine ribonucleoside (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity: 9.3 pKd

Ligand: nitrobenzylmercaptopurine ribonucleoside (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.699999809265137 pKi

Ligand: NBTGR (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.3 pKi

Ligand: KF24345 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.4 pKi
Reference (Journal): Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) with the es and ei subtypes of equilibrative nucleoside transporters.
Published in: J Pharmacol Exp Ther

Ligand: draflazine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.600000381469727 pKi
Reference (Journal): Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: dipyridamole (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1961)
Primary target: yes
Median affinity: 8.800000190734863 pKi
Reference (Journal): Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) with the es and ei subtypes of equilibrative nucleoside transporters.
Published in: J Pharmacol Exp Ther

Ligand: dilazep (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pKi
Target family: SLC32 vesicular inhibitory amino acid transporter (type: transporter)
Target: Vesicular inhibitory amino acid transporter

Ligand: vigabatrin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009), EMA (2018)
Median affinity: 2.1 pIC50
Reference (Journal): Identification and characterization of the vesicular GABA transporter.
Published in: Nature
Target family: SLC33 acetylCoA transporter (type: transporter)
Target: AcetylCoA transporter

Ligand: [14C]acetylCoA (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: SLC34 family of sodium phosphate co-transporters (type: transporter)
Target: Sodium phosphate 2

Ligand: lifastuzumab vedotin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Patent): Compositions and methods for the diagnosis and treatment of tumor.

Ligand: compound 15 [PMID: 35034442] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.190000057220459 pIC50
Reference (Journal): Discovery of Gut-Restricted Small-Molecule Inhibitors of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia.
Published in: J Med Chem
Target family: SLC36 family of proton-coupled amino acid transporters (type: transporter)
Target: Proton-coupled Amino acid Transporter 1

Ligand: ethinylestradiol (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibitory Effects of 17-&#x3b1;-Ethinyl-Estradiol and 17-&#x3b2;-Estradiol on Transport Via the Intestinal Proton-Coupled Amino Acid Transporter (PAT1) Investigated In&#xa0;Vitro and In&#xa0;Vivo.
Published in: J Pharm Sci

Ligand: indole-3-propionic acid (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 2.3 pKi
Reference (Journal): Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1.
Published in: FASEB J
Target family: SLC36 family of proton-coupled amino acid transporters (type: transporter)
Target: Proton-coupled Amino acid Transporter 2

Ligand: α-methyl-D,L-tryptophan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 2.5 pIC50
Reference (Journal): Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2).
Published in: Biochim Biophys Acta
Target family: SLC36 family of proton-coupled amino acid transporters (type: transporter)
Target: Proton-coupled Amino acid Transporter 1

Ligand: L-tryptophan (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 2.3 pKi
Reference (Journal): Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1.
Published in: FASEB J
Target family: SLC36 family of proton-coupled amino acid transporters (type: transporter)
Target: Proton-coupled Amino acid Transporter 2

Ligand: 5-hydroxy-L-tryptophan (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 2.8 pIC50
Reference (Journal): Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2).
Published in: Biochim Biophys Acta
Target family: SLC36 family of proton-coupled amino acid transporters (type: transporter)
Target: Proton-coupled Amino acid Transporter 1

Ligand: 17β-estradiol (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1954, prior history unavailable)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibitory Effects of 17-&#x3b1;-Ethinyl-Estradiol and 17-&#x3b2;-Estradiol on Transport Via the Intestinal Proton-Coupled Amino Acid Transporter (PAT1) Investigated In&#xa0;Vitro and In&#xa0;Vivo.
Published in: J Pharm Sci

Ligand: 5-hydroxy-L-tryptophan (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 3 pKi
Reference (Journal): Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1.
Published in: FASEB J

Ligand: 5-hydroxytryptamine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 2.2 pKi
Reference (Journal): Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1.
Published in: FASEB J
Target family: SLC37 family of phosphosugar/phosphate exchangers (type: transporter)
Target: Glucose-6-phosphate transporter

Ligand: S-4048 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Natural product inhibitors of glucose-6-phosphate translocase.
Published in: Medchemcomm
Target family: SLC3 family (type: transporter)
Target: 4F2hc

Ligand: IGN523 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.890000343322754 pKd
Reference (Patent): Anti-cd98 antibodies and methods of use thereof.
Target family: SLC40 iron transporter (type: transporter)
Target: Ferroportin

Ligand: LY2928057 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Patent): Anti-ferroportin 1 monoclonal antibodies and uses thereof.

Ligand: vamifeport (Synthetic organic)
Interaction type: Inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Published in: J Clin Invest
Target family: SLC42 family of Rhesus glycoprotein ammonium transporters (type: transporter)
Target: Ammonium transporter Rh type C

Ligand: [14C]methylamine (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Characterization of ammonia transport by the kidney Rh glycoproteins RhBG and RhCG.
Published in: Am J Physiol Renal Physiol
Target family: SLC42 family of Rhesus glycoprotein ammonium transporters (type: transporter)
Target: Ammonium transporter Rh type A

Ligand: [14C]methylamine (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The Rh complex exports ammonium from human red blood cells.
Published in: Br J Haematol
Target family: SLC44 choline transporter-like family (type: transporter)
Target: Choline transporter-like 1

Ligand: hemicholinium-3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pKi
Target family: SLC46 family of folate transporters (type: transporter)
Target: Proton-coupled folate transporter

Ligand: [3H]N5-methylfolate (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]methotrexate (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: [3H]folinic acid (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]folic acid (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: sulfasalazine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1950)
Median affinity: 4.2 pIC50
Reference (Journal): Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
Published in: Cell

Ligand: indomethacin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1965)
Median affinity: 3.7 pIC50
Reference (Journal): Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
Published in: Cell

Ligand: [3H]pemetrexed (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: SLC47 family of multidrug and toxin extrusion transporters (type: transporter)
Target: MATE2

Ligand: pyrimethamine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1953)
Median affinity: 6.3 pKi
Reference (Journal): Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine.
Published in: J Pharmacol Exp Ther

Ligand: cimetidine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1977)
Median affinity: 5.1 pKi
Reference (Journal): Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
Published in: J Pharmacol Exp Ther
Target family: SLC47 family of multidrug and toxin extrusion transporters (type: transporter)
Target: Multidrug and toxin extrusion

Ligand: [14C]TEA (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1.
Published in: Pharm Res

Ligand: [14C]TEA (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): A human transporter protein that mediates the final excretion step for toxic organic cations.
Published in: Proc Natl Acad Sci USA

Ligand: [14C]metformin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1.
Published in: Pharm Res

Ligand: [14C]metformin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
Published in: Biochem Pharmacol

Ligand: pyrimethamine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 7.099999904632568 pKi
Reference (Journal): Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine.
Published in: J Pharmacol Exp Ther

Ligand: cimetidine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1977)
Median affinity: 6 pKi
Reference (Journal): Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
Published in: J Pharmacol Exp Ther
Target family: SLC47 family of multidrug and toxin extrusion transporters (type: transporter)
Target: MATE2

Ligand: [14C]TEA (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
Published in: Biochem Pharmacol

Ligand: [14C]metformin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
Published in: Biochem Pharmacol
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 1

Ligand: α-Cyano-5-phenyl-2,4-pentadienic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 2

Ligand: nitrofurantoin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1953), UK (2000)
Primary target: no
Median affinity: 5.480000019073486 pIC50
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab

Ligand: mitoglitazone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.889999866485596 pIC50
Reference (Journal): Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.
Published in: Proc Natl Acad Sci U S A

Ligand: lonidamine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.
Published in: Biochem J

Ligand: lonidamine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.340000152587891 pIC50
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab

Ligand: entacapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (1998)
Primary target: no
Median affinity: 6.21999979019165 pIC50
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab

Ligand: α-cyanocinnamate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J

Ligand: α-Cyano-5-phenyl-2,4-pentadienic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J

Ligand: α-cyano-4-hydroxycinnamate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 1 like

Ligand: zaprinast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab

Ligand: nitrofurantoin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1953), UK (2000)
Primary target: no
Median affinity:  -
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab

Ligand: lonidamine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab

Ligand: entacapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (1998)
Primary target: no
Median affinity:  -
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 1

Ligand: UK-5099 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J

Ligand: mitoglitazone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.889999866485596 pIC50
Reference (Journal): Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.
Published in: Proc Natl Acad Sci U S A

Ligand: α-cyanocinnamate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 2

Ligand: UK-5099 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 1

Ligand: α-cyano-4-hydroxycinnamate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors.
Published in: Biochem J
Target family: SLC54 Mitochondrial pyruvate carriers (type: transporter)
Target: mitochondrial pyruvate carrier 2

Ligand: zaprinast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer.
Published in: Mol Metab
Target family: SLC60 Glucose transporters (type: transporter)
Target: major facilitator superfamily domain containing 4B

Ligand: phloretin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney.
Published in: J Biol Chem

Ligand: urea (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Alternative channels for urea in the inner medulla of the rat kidney.
Published in: Am J Physiol Renal Physiol

Ligand: phlorizin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney.
Published in: J Biol Chem
Target family: SLC63 Sphingosine phosphate transporters (type: transporter)
Target: SPNS lysolipid transporter 2, sphingosine-1-phosphate

Ligand: SLB1122168 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.03000020980835 pIC50
Reference (Journal): 2-Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2).
Published in: J Med Chem

Ligand: SLF1081851 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.710000038146973 pIC50
Reference (Journal): Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors.
Published in: J Med Chem
Target family: SLC65 NPC-type cholesterol transporters (type: transporter)
Target: NPC1 like intracellular cholesterol transporter 1

Ligand: ezetimibe (Synthetic organic)
Interaction type: Antagonist
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2002)
Primary target: yes
Median affinity: 6.659999847412109 pKd
Reference (Journal): The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).
Published in: Proc Natl Acad Sci USA
Target family: SLC7 family (type: transporter)
Target: L-type amino acid transporter 1

Ligand: KYT-0353 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.
Published in: Cancer Sci